United States was Bio-Techne’s largest region in fiscal 2026, bringing in $635.37M of $1.22B (52%).
| Geography | FY 2009 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $642.47M | $657.75M | $683.23M | $635.37M | |||||||||||||
| Emea, Excluding United Kingdom | $220.23M | $241.43M | $266.31M | $294.22M | |||||||||||||
| Emea, Excluding U.K | — | — | — | — | |||||||||||||
| Europe | — | — | — | — | |||||||||||||
| Apac, Excluding Greater China | $73.19M | $73.90M | $77.26M | $85.82M | |||||||||||||
| Greater China | $113.87M | $99.47M | $100.46M | $104.06M | |||||||||||||
| China | — | — | — | — | |||||||||||||
| United Kingdom | $49.46M | $50.01M | $54.83M | $56.28M | |||||||||||||
| Europe Other Than U.K | — | — | — | — | |||||||||||||
| Other Areas | — | — | — | — | |||||||||||||
| Other Asia | — | — | — | — | |||||||||||||
| Rest Of World | $37.49M | $36.50M | $37.55M | $39.29M | |||||||||||||
| Total | $1.14B | $1.16B | $1.22B | $1.22B |
Bio-Techne brought in $1.22B from its six regions in fiscal 2026, the year ended June 30, 2026. That was down 0.4% from $1.22B in fiscal 2025. United States was the largest at $635.37M (52.3%), ahead of Emea, Excluding United Kingdom at $294.22M (24.2%) and Greater China at $104.06M (8.6%). The other three regions brought in $181.38M combined.
Compared with fiscal 2025, Apac, Excluding Greater China grew fastest, up 11.1% to $85.82M, while United States fell the most, down 7.0% to $635.37M. From fiscal 2023 to 2026, combined revenue from these regions grew from $1.14B to $1.22B, a compound annual growth rate of 2.2%. United States' share of the total fell from 56.5% to 52.3%.
Protein Sciences was Bio-Techne’s largest segment in fiscal 2026, bringing in $874.62M of $1.21B (72%).
| Segment | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protein Sciences | $845.75M | $830.90M | $870.25M | $874.62M | |||||||||||||||
| Diagnostics & Spatial Biology | $292.60M | $326.39M | $346.26M | $336.37M | |||||||||||||||
| Biotechnology | — | — | — | — | |||||||||||||||
| Diagnostics & Genomics | — | — | — | — | |||||||||||||||
| United States | — | — | — | — | |||||||||||||||
| Diagnostics | — | — | — | — | |||||||||||||||
| Europe | — | — | — | — | |||||||||||||||
| Protein Platforms | — | — | — | — | |||||||||||||||
| Clinical Controls | — | — | — | — | |||||||||||||||
| Other Asia | — | — | — | — | |||||||||||||||
| Hematology | — | — | — | — | |||||||||||||||
| Rest Of World | — | — | — | — | |||||||||||||||
| China | — | — | — | — | |||||||||||||||
| Other Revenue | — | $4.15M | $4.15M | — | |||||||||||||||
| Total | $1.14B | $1.16B | $1.22B | $1.21B |
Bio-Techne brought in $1.21B from its two segments in fiscal 2026, the year ended June 30, 2026. Bio-Techne regrouped these segments after fiscal 2025, so the total does not compare directly with that year's $1.22B. Protein Sciences was the largest at $874.62M (72.2%), ahead of Diagnostics & Spatial Biology at $336.37M (27.8%).
Compared with fiscal 2025, Protein Sciences grew 0.5% to $874.62M, while Diagnostics & Spatial Biology fell 2.9% to $336.37M. From fiscal 2023 to 2026, combined revenue from these segments grew from $1.14B to $1.21B, a compound annual growth rate of 2.1%. Protein Sciences' share of the total fell from 74.3% to 72.2%.
Bio-Techne stopped reporting Other Revenue as a separate segment after fiscal 2025, when it brought in $4.15M.
Consumables was Bio-Techne’s largest product and service line in fiscal 2026, bringing in $680.85M of $910.77M (75%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Consumables | $665.30M | $657.68M | $684.17M | $680.85M | ||||||
| Instruments | $112.09M | $108.27M | $112.09M | $110.63M | ||||||
| Services | $85.78M | $99.27M | $111.57M | $94.30M | ||||||
| Service | — | — | — | — | ||||||
| Royalty | $21.10M | $23.35M | $23.69M | $24.99M | ||||||
| Total | $884.27M | $888.56M | $931.51M | $910.77M |
Bio-Techne brought in $910.77M from its four product and service lines in fiscal 2026, the year ended June 30, 2026. That is less than the $1.22B it reports by geography, so these lines do not cover all of its revenue. Consumables was the largest at $680.85M (74.8%), ahead of Instruments at $110.63M (12.1%) and Services at $94.30M (10.4%). The remaining line, Royalty, brought in $24.99M.
Compared with fiscal 2025, Royalty grew fastest, up 5.5% to $24.99M, while Services fell the most, down 15.5% to $94.30M.
Bio-Techne (TECH) reports its revenue by geography, by segment and by product and service. In fiscal 2026, United States was its largest region, bringing in $635.37M (52.3% of the total), followed by Emea, Excluding United Kingdom at $294.22M (24.2%).
United States was Bio-Techne's largest region in fiscal 2026, bringing in $635.37M, or 52.3% of the $1.22B total across its six regions.
Protein Sciences was Bio-Techne's largest segment in fiscal 2026, bringing in $874.62M, or 72.2% of the $1.21B total across its two segments.
Consumables was Bio-Techne's largest product and service line in fiscal 2026, bringing in $680.85M, or 74.8% of the $910.77M total across its four product and service lines.
Among Bio-Techne's regions that make up at least 2% of revenue, Apac, Excluding Greater China grew fastest in fiscal 2026, up 11.1% from $77.26M to $85.82M.
Every figure comes from Bio-Techne's annual financial filings, as reported. Each line keeps the name Bio-Techne gives it, and years follow its fiscal calendar.
Bio-Techne's revenue by geography goes back to fiscal 2009, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.